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Background: The concentrations of three N-acylethanolamines (NAEs), anandamide
(AEA), N-oleoylethanolamide (OEA), and N-palmitylethanolamide (PEA) are increased in
the endometria of women with endometrial cancer (EC). It is widely accepted that plasma
levels of these three NAEs are regulated by the actions of the rate-limiting enzymes
N-acylphoshatidylethanolamine-specific phospholipase D (NAPE-PLD) and fatty acid
amide hydrolase (FAAH), which are synthesizing and degradative, respectively. The
expression and activity of these enzymes have not previously been studied in EC.
Methods: FAAH activity in peripheral blood lymphocytes, and transcript and protein
expression for FAAH and NAPE-PLD in EC tissues were measured using enzyme,
quantitative RT-PCR, and histomorphometry (of immunoreactive tissue sections),
respectively. Samples were from 6 post-menopausal women with atrophic endometria
(controls) and 34 women with histologically diagnosed EC. Concentrations of the three
NAEs also measured in plasma and tissues were correlated with lymphocytic FAAH
activity and the NAPE-PLD and FAAH transcript and protein levels.
Results: Peripheral lymphocyte FAAH activity was unaffected in women with EC
compared to controls. The FAAH transcript expression level was significantly (p< 0.0001)
75% lower in EC whilst NAPE-PLD levels were not significantly (p = 0.798) increased. In
line with the transcript data, a significant (p < 0.0001) tumor type-dependent 70–90%
decrease in FAAH protein and significant 4- to 14-fold increase in NAPE-PLD protein
(p < 0.0001) was observed in the malignant tissue with more advanced disease
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having lower FAAH and higher NAPE-PLD expression than less advanced disease.
Correlation analyses also confirmed that tissue NAE concentrations were inversely
related to FAAH expression and directly correlated to NAPE-PLD expression and the
NAPE-PLD/FAAH ratio.
Conclusion: These data support our previous observation of tissue levels of AEA, OEA,
and PEA and a role for NAE metabolism in the pathogenesis of EC.
Keywords: endocannabinoids, endometrial cancer, fatty acid amide hydrolase, gene expression,
immunohistochemistry, N-acylphoshatidylethanolmine-specific phospholipase D
INTRODUCTION
The levels of the endocannabinoids N-arachidonylethanolamine
(anandamide; AEA), N-palmityolethanolamine (PEA), and N-
oleoylethanolamine (OEA) have been shown to be higher in
endometrial cancer tissue of post-menopausal women when
compared to that of controls (1). The key enzymes of
the endocannabinoid system, N-acylphoshatidylethanolamine-
specific phospholipase D (NAPE-PLD) and fatty acid amide
hydrolase (FAAH), which are respectively involved in the
synthesis and degradation of some of the endocannabinoids,
have also been shown to be expressed and regulated in
normal endometrium (2–4). Since AEA, OEA and PEA levels
are higher in endometrial cancer tissues (1), we adduced
that either a reduction in FAAH expression, or an increase
in NAPE-PLD expression, or both, occurring simultaneously,
might be responsible for the observed higher tissue levels
of these endocannabinoids (collectively referred to as N-
acylethanolamines or NAEs).
The implications of these observations and conclusions are
that both the changes in NAEs and their enzymes might be
involved in the pathogenesis of endometrial cancer. While the
expression patterns and activities of the enzymes have been
studied in various tissues (3, 5) and peripheral lymphocytes (6–
9), to the best of our knowledge they have not been studied in
patients with endometrial cancer (EC).
The aim of this study was therefore to investigate the changes
in these endocannabinoid system components in endometrial
cancer. This was achieved throughmeasurement of the transcript
levels of FAAH and NAPE-PLD in endometrial biopsies of post-
menopausal women with or without EC and by correlating
these with measurements of their respective protein levels.
Additionally, lymphocytic FAAH activity was examined and
correlated with plasma AEA, OEA and PEA concentrations to
determine whether the observed higher plasma AEA and PEA
concentrations in women with EC are primarily a function of
endometrial tissue or lymphocytic FAAH expression.
MATERIALS AND METHODS
Participants
Volunteers were women undergoing a hysterectomy for either
endometrial carcinoma (study group) or a benign gynecological
condition, such as uterine prolapse (control group), at the
University Hospitals of Leicester National Health Service Trust.
All provided signed informed consent to take part in the
study, which had Ethical approval from the Leicestershire,
Nottinghamshire, and Rutland Research Ethics Committee.
Exclusion criteria were those women currently on or had been on
hormonal treatment (such as hormone replacement therapy or
the levonorgestrel intrauterine system) in the preceding 3months
or currently on prescription or recreational drugs. Women with
chronic medical conditions or any other type of cancer were also
excluded. The number of subjects and details of the types of EC
and basic demographics are shown in Table 1.
Patient Characteristics for the FAAH
Activity Assay
Only type 1 EC patients were included for the measurement
of lymphocytic FAAH enzyme activity in EC, because these
women had been shown to have the highest plasma AEA and
PEA concentrations (1). There were no differences in the ages
and BMIs of the type 1 EC patients (cases) and controls (non-
malignant cases) (Table 1A). Similarly, there were no significant
differences in the ages and BMIs of women with types 1 and
2 EC and the controls who provided samples for the qRT-PCR
(Table 1B) or the immunohistochemistry studies (Table 1C).
Sample Collection
Whole Blood
For FAAH activity measurements, venous blood (2.7ml) was
collected into pre-filled monovettes with acid citrate dextrose
(ACD) anticoagulant (ACD to blood ratio 1:10). After mixing,
samples were stored immediately at−80◦C for later studies.
Endometrial Tissues
Fresh uteri obtained at hysterectomy were immediately
transported on ice to the histopathology department where
endometrial biopsies were obtained by a consultant gynecological
histopathologist. The biopsies were divided into two; one for the
measurement of transcript levels and the other for histological
confirmation of the diagnosis and immunohistochemistry
(IHC). Both cancer and normal tissue biopsies were washed
with phosphate buffered saline (PBS) to remove excess blood
and thereafter immediately stored in either RNAlater R© (Life
Technologies, Paisley, UK) for 24 h before being stored at−80◦C
for later RNA extraction or fixed in 10% formalin and embedded
in paraffin wax for histological confirmation of the diagnosis
and immunohistochemistry (IHC). Sections (4µm) of the wax
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TABLE 1 | Details of the patients’ ages and BMI within the three indicated studies.
(A) FAAH ENZYME ACTIVITY STUDY
Tissue type Atrophic endometrium (6) Type 1 EC (15) Type 2 EC (0)
Age (years) 60.67 ± 4.27 63.87 ± 11.11 n.d.
BMI (kg/m2 ) 26.67 ± 6.50 33.13 ± 6.64 n.d.
(B) qRT-PCR EXPRESSION STUDY
Tissue type Non-malignant Type 1 EC Type 2 EC
Designation Atrophic (6) Grade 1 (6) Grade 2 (6) Grade 3 (3) Serous (3) Carcinosarcoma (3)
Age (years) 60.67 ± 4.27 66.17 ± 16.14 66.50 ± 10.25 72.67 ± 12.06 59.00 ± 3.46 50.00 ± 5.00
BMI (kg/m2 ) 26.67 ± 6.50 33.50 ± 8.92 32.00 ± 5.97 35.33 ± 6.11 37.67 ± 2.52 36.67 ± 6.43
(C) ICC EXPRESSION STUDY
Tissue type Non-malignant Type 1 EC Type 2 EC
Designation Atrophic (6) Grade 1 (6) Grade 2 (6) Grade 3 (6) Serous (4) Carcinosarcoma (6)
Age (years) 60.67 ± 4.27 62.50 ± 13.90 65.17 ± 9.86 66.83 ± 7.88 70.25 ± 10.97 58.33 ± 7.42
BMI (kg/m2 ) 26.67 ± 6.50 33.00 ± 8.760 34.83 ± 5.56 31.50 ± 3.08 33.00 ± 6.83 35.50 ± 5.99
Data in all tables are presented as the mean ± SD for both age and BMI. The numbers of samples are indicated in parentheses after the designated tissue types. Samples taken from
the different groups were not significantly different to the atrophic endometrium (control); Dunnett’s post-test, one-way ANOVA. EC, endometrial cancer; n.d., not determined.
embedded biopsies were cut with a microtome, placed on saline-
coated slides and allowed to dry. After drying, representative
sections were first subjected to hematoxylin and eosin (H&E)
staining for histological confirmation of disease. This was kindly
performed by a senior gynecological pathology consultant.
RNA Extraction and cDNA Synthesis
Endometrial tissues biopsies (100mg) were removed from
the RNAlater R© and placed into lysis/binding buffer [1ml
lysis/binding buffer solution per 100mg of tissues (miRNA
Isolation Kit)] before disruption and homogenization using a
TissueRuptor (Qiagen Crawley, UK) homogenizer at medium
speed for 60 s on ice. The tissue was homogenized until all
visible “clumps” were dispersed and total RNA extracted using
the mirVanaTM miRNA isolation kit (Life Technologies, Paisley,
UK) according to the manufacturer’s protocol. Total RNA was
quantified and its purity determined using a NanoDrop 2000c
spectrophotometer (Thermo Scientific, Detroit, MI, USA). At
this point, the RNA concentration was standardized to 10µg/100
µl, and genomic DNA digested by treating with a TURBO-
DNAse (Life Technologies, Paisley, UK) at 37◦C for 30min.
The DNAse reaction was inactivated with 10 µl of inactivation
buffer and the solution centrifuged at 4◦C for 90 s at 10,000 ×
g. Supernatants were subjected to first strand synthesis using
the high capacity cDNAMultiScribeTM Reverse Transcriptase Kit
(Life Technologies, Paisley, UK) according to the manufacturer’s
protocol; incubation at 25◦C for 10min, 37◦C for 120min,
85◦C for 5min, and then cooled to 4◦C. The cDNA was stored
at−20◦C.
Quantitative Real-Time PCR
Quantitative Real-Time PCR experiments were performed using
the validated human endogenous control assay TaqMan R©
Array 96-Well Plates consisting of 3 reference genes previously
demonstrated to be the correct endogenous genes for atrophic
and EC endometrial samples (10). Each TaqMan R© gene
expression assay consisted of a fluorogenic FAMTM dye–labeled
MGB probe and two amplification primers (forward and reverse)
provided in a pre-formulated 20× mix; 1× final concentrations
were 250 nM for the probe and 900 nM for each primer.
Each assay had an amplification efficiency of 100 ± 10%1.
The TaqMan R© gene expression arrays were purchased from
Applied Biosystems (Life Technologies, Paisley, Scotland, UK).
The TaqMan R© human FAAH (Hs01038660_m1) andNAPE-PLD
(Hs00419593_m1) primers and probes were similarly purchased
from Applied Biosystems, as FAM/MGB dye-labeled probes.
Validated Taqman R© endogenous control reference genes used
for normalization of the FAAH and NAPE-PLD gene expression
were all VIC/TAMARA dye labeled assays purchased from
Applied Biosystem and were; MRPL19 (Hs00608519_m1), PPIA
(Hs99999904_m1), and IPO8 (Hs00183533_m1). RT-minus and
no template controls (NTC) containing DNAse-free water
instead of template mRNA were included in each run. No
product was synthesized in the NTC and RT-minus confirming
the absence of contamination with exogenous DNA. All reactions
were performed in the final volume reaction of 20µl consisting of
2 µl of cDNA, 8 µl of DNAse-free water and 10 µl of TaqMan R©
universal PCR Master Mix. The plates were run on a StepOne
Plus instrument (Applied Biosystem) and the thermal cycler
profile used was: 2min at 50◦C, 10min at 95◦C, and then 40
cycles of 15 s at 95◦C and 1min at 60◦C. All the reactions for
1Technologies, L. Amplification Efficiency of TaqMan R© Gene Expression Assays.
Life Technologies Application Note: lifetechnologies.com (accessed October 19,
2019).
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the reference genes were performed in triplicate (both biological
and technical).
Identification, Localization, and Histomorphometric
Analysis of NAPE-PLD and FAAH Protein Expression
Immunolocalization was performed using antibodies against
FAAH (1:2,000; Alpha Diagnostics International, San Antonio,
TX, USA) and NAPE-PLD (1:50; SIGMA Life Science,
Stockholm, Sweden), with standard immunohistochemistry
protocols as previously described (2, 3, 11–13). For negative
controls, the slides were incubated with rabbit IgG diluted
to the same concentrations as the primary antibodies (see
Supplemental Figures 1, 2). Photomicroscopy images were
taken on an Axioplan transmission microscope (Carl Zeiss
Ltd., Welwyn Garden City, Hertfordshire, UK) equipped with
a Sony DXC-151P analog camera (Sony Inc., Tokyo, Japan)
connected to a computer, running an Axiovision image capture
and processing software (Axiovision version 4.4; Carl Zeiss Ltd.).
All images were captured at 200× magnification and analyzed
using image analysis software (ImageScope version 10.2.2.2319;
Aperio Technologies, Inc., Vista, CA) as previously described
(2, 12, 14). Immunoreactivity (unbiased histoscore, H-score)
was assessed semi-quantitatively by assigning scores as 0 (no
staining), 100 (week staining), 200 (moderate staining), and
300 (strong staining) as determined by the software algorithm.
The H-score values for the glands and stroma were determined
independently and then combined to provide an overall H-score
for the entire tissue.
Quantification of the FAAH Enzyme Activity in
Peripheral Blood Lymphocytes
Lymphocytes were isolated from whole blood using the methods
described by Maccarrone et al. (6), and were homogenized in
ice-cold 50mM Tris-HCl (pH 7.4) buffer and centrifuged three
times at 1,000 × g for 10min each at 4◦C, with the pellet
discarded after each centrifugation. FAAH activity was assayed
in the supernatants by incubation with [14C]-AEA labeled on
the ethanolamine moiety (ARC, St. Louis, MO, USA) at 37◦C
for 15min in Tris-HCl buffer (pH 9.0). The reaction was
stopped by the addition of ice-cold chloroform/methanol (2:1
v/v) and mixed thoroughly by vortexing and then centrifuged
in order to separate the water-soluble [14C]-ethanolamine from
residual anandamide. The radioactivity was then measured by
scintillation counting as reported by Bari et al. (15).
Statistical Analysis
Statistical analysis of the data was performed using Prism
version 6.00 for windows (GraphPad Software, San Diego
CA, USA, www.graphpad.com). Data that did not follow a
Gaussian distribution were expressed as medians and inter-
quartile range (IQR) and comparison between groups performed
using Mann-Whitney U-test or one-way analysis of variance
(ANOVA) followed by Kruskal-Wallis multiple comparisons
analysis. Conversely, normally distributed data were analyzed
by parametric one–way ANOVA with Dunnett’s ad hoc post-
analysis. In all cases a p < 0.05 was considered to be significant.
Correlations were performed using Pearson correlation analyses.
RESULTS
FAAH Enzyme Activity in Peripheral
Lymphocytes Is Unaffected by Disease
Although the median (IQR) FAAH enzyme activity levels of
136.0 pmol/min/mg protein (125.0–165.0) in the lymphocytes
of the EC group were higher than the 131.0 pmol/min/mg
protein (125.0–149.3) in the control group; the difference was not
statistically significant (p= 0.635) (Figure 1A). A sub-analysis of
FAAH enzyme activities in the lymphocytes from the different
grades of type 1 EC showed a level of 150.0 pmol/min/mg protein
(120.0–170.5) in grade 1 EC, 135 pmol/min/mg protein (126.3–
159.5) in grade 2 EC and 118 pmol/min/mg protein (103.0–133.0)
in grade 3 EC (Figure 1B). These data were again not statistically
different from that of the controls (p = 0.519), although the
FAAH activity was increased in grade 1 and 2 EC but not in grade
3 EC (Figure 1B). There was a significant inverse correlation
between plasma AEA concentrations and lymphocytic FAAH
activity (r2 = 0.333; p = 0.008) (Figure 1C) and between plasma
OEA concentrations and lymphocytic FAAH activity (r2 = 0.219;
p = 0.032) (Figure 1D), but not between lymphocytic FAAH
activity and plasma PEA concentrations (r2 = 0.212; p = 0.055),
although this was also an inverse relationship (Figure 1E).
Tissue FAAH Transcript Levels Are
Increased and NAPE-PLD Transcript
Levels Are Unaffected in EC
The transcript levels for FAAH andNAPE-PLD, as determined by
qRT-PCR relative to the geometric mean of three housekeeping
genes (10), are shown in Figure 2. There was a gradual decrease
in levels of FAAH transcript with tumor grade; with the
highest levels of 0.445 (0.230–0.720; median and IQR) observed
in atrophic endometria (controls). The levels were lower at
0.114 (0.080–0.259) for grade 1 EC, and 0.152 (0.119–1.198)
for grade 2 and 0.109 (0.076–0.120) for grade 3 tumors and
lower still at 0.039 (0.028–0.040) in serous cancer tissues and
0.028 (0.005–0.038) in carcinosarcoma tissue (Figure 2A). The
levels in type 1 and 2 EC tissues were significantly lower
(p < 0.01 and p < 0.001, respectively) than those found in
control tissues.
The levels of the NAPE-PLD transcripts are shown in
Figure 2B. Unlike the transcript levels for FAAH, these were not
significantly different in any of the endometrial cancer types or
grades when compared to control atrophic tissues (Figure 2B).
FAAH Protein Levels Are Decreased and
NAPE-PLD Protein Levels Are Increased in
EC Tissues
After examining the levels of FAAH and NAPE-PLD transcripts
in the different types of EC, the next step was to determine
where in the tissue the proteins for these enzymes were being
expressed and to confirm that the transcript changes were
reflected at the protein level, by using immunohistochemistry
(IHC). The details of the optimization steps taken to develop
the two antibodies for FAAH and NAPE-PLD are provided
in Supplemental File 1. The data indicate that both antibodies
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FIGURE 1 | FAAH activity in peripheral blood lymphocyte membranes and relationship to plasma endocannabinoid concentrations. (A) Shows the FAAH activities
[presented as median (IQR and range)] in lymphocyte membranes isolated from women with type 1 endometrial cancer (EC; n = 6) compared to that of
post-menopausal women with atrophic endometria (control; n = 15). The EC group was subsequently divided into the different grades of type 1 EC (B) with (n = 6;
control group), grade 1 (n = 9), grade 2 (n = 4), and grade 3 (n = 2). Spearman correlation analyses between lymphocytic FAAH activity and plasma AEA
concentrations (C; n = 19), OEA concentrations (D; n = 21), and PEA concentrations (E; n = 18) are shown together with the Spearman’s coefficient (r2 ) and p-value.
Differences in FAAH activities (A) were examined by Mann-Whitney U-test and by Kruskal-Wallis one-way ANOVA with Dunn’s multiple comparisons test (B); ns, not
significantly different. The numbers in parentheses represent the number of samples tested in each group.
FIGURE 2 | Relative expression of NAPE-PLD and FAAH transcript levels via qRT-PCR. The expression of NAPE-PLD transcripts (A) and FAAH transcripts (B) relative
to the geometric mean of three housekeeping genes (IPO8, MRPL19, and PPIA) are shown for control (atrophic) endometria (A; n = 6), grade 1 (G1; n = 6), grade 2
(G2; n = 6), and grade 3 (G3, n = 3) type 1 EC tissue and serous (S, n = 3), and carcinosarcoma (C, n = 3) type 2 EC tissue. Data are presented as median (IQR).
P-values were obtained using Kruskal-Wallis one ANOVA with Dunn’s multiple comparisons test (**p = 0.0044; ***p = 0.0009). The numbers in parentheses represent
the number of samples tested in each group.
were specific for their intended antigens (data shown in
Supplemental File 1).
FAAH Protein Expression Is Decreased in
EC Tissues
Figure 3A shows the staining pattern of FAAH in a representative
atrophic (control) endometrium and representative EC samples.
Immunoreactive FAAH staining intensity was strong to very
strong in both stroma and glands of atrophic endometria.
In atrophic endometria, immunoreactive FAAH protein was
expressed at higher levels in the glands than in the stroma with
a stronger immunoreactive intensity along the basal region of
the glands compared to the apical region. As might be expected
from atrophic endometria, the number and size of glands were
markedly reduced in the atrophic endometrium compared to all
the other tissues (16).
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FIGURE 3 | FAAH immunoreactivity decreases in endometrial cancer. (A) Shows representative photomicrographs of immunoreactive FAAH staining in atrophic
endometria and grade 1, 2, 3 type 1 EC, and serous and carcinosarcoma type 2 EC. Note the gradual change of staining in the glandular epithelial cells (g) from less
to more advanced malignancy. Also note that FAAH immunoreactivity is higher in stromal cells of the atrophic endometrium than in any of the EC tissues, and the
presence of cystic glands and normal glands in the serous EC samples. (B) Shows data from the histomorphometric analyses of the glands alone (G, left panel) and
stromal tissue alone (S, middle panel) and for the entire tissue (G + S, right panel). The H-scores for FAAH staining was statistically significantly decreased in all the EC
when compared to the atrophic endometria. The results are presented as means ± SD, with one way analysis of variance with Dunnett’s ad hoc post-test analysis
used to determine the p-values; ****p < 0.0001 compared to atrophic; n = 6 in all cases except for serous EC (where n = 4) and numbers are shown in parentheses
above each bar. Error bars are not shown when encompassed by the data.
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FAAH staining in the stroma of atrophic endometria was
stronger than in the stroma of other tissues and weaker than that
in the glands of all tissues (Figure 3A). FAAH staining was also
primarily localized to the plasma membrane of cells, with some
staining demonstrated in the cytoplasm and the nucleus, whereas
in other tissues, it was absent from the nuclei, but visibly attached
to the nuclear membranes (see panels iii–v). FAAH staining
intensity in grade 2 EC was very low compared to the atrophic
group, with weaker staining in both the glands and stroma. In
the glands, FAAH staining was localized more in the cytoplasm,
with more intensity toward the apical region of the glands, with
the nuclear envelope only slightly stained.
FAAH staining in carcinosarcoma (panel vi) showed very
low intensity compared to that observed in the atrophic group,
but involved both the glands and stroma. It was difficult to
see the glandular structure in the carcinosarcoma, because the
glands had been broken down and the epithelial cells dispersed
throughout the tissue, but in those epithelial cells that were
visible, FAAH staining was more cytoplasmic and localized to the
apical region. Consistent with the staining in other tissues, the
nuclear envelope and the nucleus had taken some staining. This
was observed in both the glands and stroma. Histomorphometric
analysis of these data confirmed the visual staining patterns in
the glands alone, the stroma alone, or when the glands and
stroma were combined (Figure 3B), with FAAH protein levels
(measured as H-score) in the glands and stroma combined (right
panel) being significantly lower (P < 0.0001) in all the various
grades of type 1 [grade 1 (172.9 ± 0.76), grade 2 (169.5 ± 0.64),
and grade 3 (120.3± 2.23)] and type 2 EC [serous (146.5± 1.94)
and carcinosarcoma (39.18 ± 2.50)] compared to the atrophic
control tissue (383.3± 1.10).
NAPE-PLD Protein Expression Is Increased
Complementary staining patterns for the NAPE-PLD antibodies
are shown in Figure 4A. In control endometria, NAPE-PLD
immunoreactivity was found in the glandular epitheliumwith the
most intense staining observed in the basal region of the glands,
and away from the lumen. No significant immunoreactivity was
demonstrated in the stroma. Although NAPE-PLD staining was
demonstrated in the cell cytoplasm, no staining was found in
the nucleus (Figure 4A, panel i). NAPE-PLD staining intensity
in grade 1 EC was slightly higher when compared to that of the
control tissue. The staining pattern was similar to that of atrophic
tissue where it was absent from the stroma, whilst that in the
glands was mainly in the cytoplasm with most nuclei not stained
(panel ii). By contrast, NAPE-PLD staining intensity in grade 2
EC was more intense being greater than that of both the atrophic
and grade 1 EC. Again, stroma was devoid of any staining, which
was confined to the glands, where it was denser in the cytoplasm
but unlike the atrophic and grade 1 EC, involved the nucleus
(panel iii). NAPE-PLD staining intensity in grade 3 EC was most
intense and was dramatically higher compared to the previously
described groups. The staining was clearly mild in the stroma,
but was very dense in the glands, where staining was found in
both the cytoplasm and nucleus. In addition, some staining of
NAPE-PLD was observed in the nuclei of stromal cells (panel iv).
NAPE-PLD staining in serous EC (panel v) was also higher
when compared to that of the atrophic, grade 1 and grade
2 EC samples, but slightly lower than in the grade 3 EC,
primarily because of decreased staining in the stroma. The
staining involved both the glands and the stroma, but the glands
were notably bigger compared to any other groups and stained
intensely with NAPE-PLD antibodies. In the glands, the staining
was denser in the cytoplasm and also present in the nucleus.
Wherever the glands appeared “stretched” giving a very big cyst-
like appearance; the glandular epitheliumwere stretched and very
thin and had comparably lower NAPE-PLD immunoreactivity.
In addition, NAPE-PLD was also found in the nuclei of these
glandular epithelial cells with surrounding stromal cells showing
both nuclear staining and light staining in the cytoplasm (panel
v). NAPE-PLD staining intensity in carcinosarcoma EC was
increased dramatically when compared to all the other categories,
especially when compared to the atrophic (control) group. The
staining involved both the glands and the stroma, with staining
being denser in the epithelial cytoplasm and nucleus. In addition,
NAPE-PLD staining was observed in the stromal cell nucleus
(panel vi). Histomorphometric analysis of these data confirmed
the visual staining patterns in the glands alone, the stroma alone,
or when the glands and stroma were combined (Figure 4B)
where the amount of immunoreactive NAPE-PLD in the entire
tissue was higher in the EC compared to the atrophic endometria.
The H-score for the types and grades of EC showed comparable
data from the glandular and stromal tissues with the lowest
combined H-score (26.02 ± 2.76) found in the atrophic tissues.
NAPE-PLD H-scores were significantly higher in all the various
grades of type 1 EC tissue (p < 0.0001) [grade 1 (96.48 ± 8.20),
grade 2 (132.8 ± 3.10), grade 3 (360.9 ± 11.03)], as were the
H-scores for the type 2 EC tissues [serous (278.9 ± 10.02) and
carcinosarcoma (301.1± 13.10)].
The Relationship Between NAPE-PLD and
FAAH Expression
Figure 5 shows the relationships between NAPE-PLD and FAAH
transcript levels and their respective protein levels (H-score in the
whole tissue) for all the combined EC samples. The data indicate
that NAPE-PLD transcript (Figure 5A) and tissue proteins
(Figure 5B) were increased in EC (albeit only the H-Score values
were significantly different) and the FAAH transcript (Figure 5C)
and protein levels (Figure 5D) were significantly decreased in
EC. There was no relationship between the levels of NAPE-
PLD and FAAH transcript (Figure 5E), but there was a strong
inverse correlation (r2 = 0.6213; p < 0.0001) between the H-
sores for NAPE-PLD and FAAH protein levels (Figure 5F) in
the tissues. An examination of the NAPE-PLD/FAAH ratios
for the transcripts and proteins showed that both transcript
(Figure 5G) and protein (Figure 5H) were significantly increased
in the EC tissue.
DISCUSSION
Both FAAH and NAPE-PLD protein expression were altered
in the endometria of women with EC when compared with
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FIGURE 4 | NAPE-PLD immunoreactivity increases in endometrial cancer. (A) Shows representative photomicrographs of immunoreactive NAPE-PLD staining in
atrophic endometria and grade 1, 2, 3 type 1 EC, and serous and carcinosarcoma type 2 EC. Note the gradual change of staining in glandular epithelial cells (g) from
the less to more advanced malignancy. Also note the apparent lack of staining in the stromal cells of the atrophic endometria. (B) Shows data from the
histomorphometric analyses of the glands alone (G, left panel) and stromal tissue alone (S, middle panel) and for the entire tissue (G + S, right panel). NAPE-PLD
staining was statistically significantly increased in all the EC when compared to the atrophic endometria. The results are presented as means ± SD. Statistical
significance was determined using one way analysis of variance with Dunnett’s ad hoc post-test analysis; ****p < 0.0001 compared to atrophic; n = 6 in all cases
except for serous EC (where n = 4). The sample numbers are shown in parentheses above each bar.
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FIGURE 5 | Comparison of the relative levels of transcripts for NAPE-PLD and FAAH with H-scores for the presence of protein. (A,B) Show the relative expressions of
NAPE-PLD transcripts and protein, respectively in the atrophic tissue (atrophic control, n = 6) and the EC cohort (n = 21 for qRT-PCR and n = 28 for IHC). The data
show similar patterns of expression with NAPE-PLD transcripts and protein increased in the EC group. Similarly, (C,D) show the relative expressions of FAAH
transcript and protein in the same groups and show decreased transcript and protein expression in the EC group. (E) Shows that the expression of NAPE-PLD
transcript does not correlate with FAAH transcript levels, but there is a good inverse correlation between NAPE-PLD and FAAH protein (F). The qRT-PCR data (A,C)
are presented as median (IQR) and analyzed using Mann-Whitney U-test, whilst the H-score data (B,D) are presented as mean ± SEM and analyzed by unpaired
Student’s t-test; ***p < 0.001; ****p < 0.0001. The number of samples analyzed is shown in parentheses above each group. Correlation was determined by Spearman
correlation with the calculated coefficients and p-values indicated on the graphs. Error bars are not shown when encompassed by the data. The NAPE-PLD: FAAH
ratios for transcript (G) and protein (H) were determined for the atrophic (control, n = 6) tissue and for EC (n = 28) tissue and the results plotted for each individual
patient recruited. The longer horizontal bar indicates the mean for the data whilst the shorter horizontal bar indicates the SD for the group. The p-values for the
transcript ratio difference (*p = 0.0208) and the protein ratio difference (****p < 0.0001) were calculated using Welch’s correction for Student’s two sided unpaired
t-test for unequal variances. Error bars are not shown when encompassed by the data. The number of samples assayed is shown in parentheses above each bar.
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atrophic controls; FAAH was decreased whilst NAPE-PLD was
increased. Since these metabolizing enzymes are responsible
for controlling “steady state” levels of the NAEs, particularly
AEA (17), they could be responsible for the increased AEA
and PEA levels we previously reported for EC tissues (1). The
lack of correlation between plasma NAE concentrations and
lymphocytic FAAH activity in all the tumor grades (Figure 1),
suggest that a concomitant loss of FAAH expression and an
increase in NAPE-PLD expression in the endometrium is a
possible reason for the observed higher levels of these NAEs in
endometrial cancer, especially Type 1 EC. This is supported by
the observation of significantly highermRNA and protein NAPE-
PLD/FAAH ratios in EC (Figure 5). Additionally, there was a
good correlation between OEA levels and NAPE-PLD/FAAH
expression ratios (Figure 1) indicating that although this NAE
may be involved in the pathogenesis of endometrial cancer (1),
its production is regulated by alterations in the activities of
NAPE-PLD and FAAH at the tissue level rather than at the
lymphocytic level.
It is often thought that if transcript levels are altered, then
the protein levels of that gene transcript should be altered in the
same manner (18); a phenomenon known as the “central dogma”
of molecular biology. This, however, is not always the case (19),
as has previously been demonstrated for FAAH and NAPE-
PLD (20). We therefore, examined the possibility that protein
expression does not exactly mirror the pattern of transcript
expression and found that this indeed was the case for NAPE-
PLD here, where the transcripts were not significantly higher
in EC, but the protein levels were. These data suggest that only
FAAH expression is likely to be involved in the modulation of
tissue AEA, OEA and PEA levels in EC (1). We could have
used immunoblotting techniques to complement the transcript
experiments, but immunoblotting techniques do not indicate
where a protein is synthesized or might act. We therefore used
previously characterized quantitative IHC methods (2, 3, 11, 13)
for the expression of FAAH and NAPE-PLD in EC. The findings
mirrored the expected pattern of altered enzyme expression
which varied with the type of tumor.
Tumor grading systems are often related to prognosis in EC
with type 2 tumors consideredmore “aggressive” because they are
independent of estrogen and furthermore are refractory to some
conventional anti-hormonal treatments (21). To reduce internal
experiment variations NAPE-PLD:FAAH ratios were calculated,
as has been conducted before (22). This allowed the relationship
between tumor grade and the expression of the enzymes to
become more apparent, with a higher NAPE-PLD:FAAH ratio
in higher tumor grades and thus more aggressive tumors.
These data support the observed higher in plasma AEA and
PEA levels that we have previously reported and suggest that
they could be good biomarkers for identifying patients with
EC (5).
To the best of our knowledge, this is the first study to quantify
FAAH enzyme activity in the lymphocytes of post-menopausal
women with either atrophic endometria or EC. Our data add
to the generalized knowledge on the functions of NAPE-PLD
and FAAH; two important regulatory enzymes considered to be
“gate-keepers” in the production and degradation of NAEs, such
as AEA, PEA, and OEA (17). These have allowed us to generate
a working hypothesis on how the entire endocannabinoid system
might be involved in EC (Figure 6) and opens up the potential to
investigate targets for future research.
Whilst there have been no studies that have examined the
activity of FAAH and NAPE-PLD in gynecological cancers,
these have been studied in early pregnancy complications.
For example, Maccarrone et al. (6), found that low FAAH
activity and high AEA tissue/plasma levels were associated with
miscarriage. Also interesting were the findings of decreased
FAAH activity without any associated change in NAPE-PLD
expression in ectopic pregnancy (13). These data suggest that
in non-malignant states, the main controlling factor for plasma
NAE concentrations is likely to be FAAH expression and
activity. Although our data show that peripheral lymphocytic
FAAH activities are however decreased in endometrial cancer
compared to the atrophic controls, this reduction failed to reach
statistical significance, probably due to the small number of
samples studied. The lower lymphocytic FAAH activity only
partly explains the higher plasma AEA concentration (1), as there
was a strong statistically significant inverse correlation between
plasma AEA and lymphocytic FAAH activity. The statistically
significant inverse correlation with plasma OEA concentrations
may be explained by the “entourage effects” of FAAH (25,
26), whereby one or more endocannabinoids are preferentially
degraded, thereby potentiating the levels of AEA.
There is some evidence that FAAH and NAPE-PLD enzyme
activities are directly linked to their expression (6, 27, 28). In the
light of lack of enzyme activity data in the tissues we studied,
the expression of the enzymes at the transcript and protein levels
were used as surrogates for activity data and showed that FAAH
transcript levels were significantly (p < 0.0001) lower by 75% in
malignant tissue. Sub-analysis of the two types of EC (Figure 2A)
revealed that FAAH transcript levels were significantly lower by
73.3% in type 1 EC and by 93.3% in type 2 EC when compared
to controls. When FAAH transcript levels were evaluated in the
various grades of cancer, they were lower in grades 1, 2, and 3
type 1 tissues and higher in type 2 serous and carcinosarcoma
EC when compared to the controls (even though these data were
not statistically different). Nevertheless, the data suggest that the
higher plasma AEA and PEA concentrations could be controlled
by the lower expression of FAAH transcript in the endometrium.
NAPE-PLD transcript levels were higher in EC but did not
reach statistical significance when compared to atrophic controls.
An interesting observation was that the expression of NAPE-PLD
and FAAH transcripts appeared to be inversely related; whilst
FAAH increased, NAPE-PLD decreased, suggesting that these
two enzymes have a common regulator. This was supported by
the NAPE-PLD/FAAH ratio, where a clear difference between
controls and EC (Figure 5) became apparent.
The data for NAPE-PLD and FAAH protein expression
followed a similar pattern to that of the transcript expression,
however, the differences observed were statistically significant,
with the H-scores for FAAH being lower in all EC tissues and
those for NAPE-PLD all being significantly higher, regardless
of grade. These data suggest that protein measurements of
enzyme expression are better than transcript measurements in
Frontiers in Oncology | www.frontiersin.org 10 December 2019 | Volume 9 | Article 1363
Ayakannu et al. FAAH and NAPE-PLD Expression in Endometrial Cancer
FIGURE 6 | Working hypothesis on how FAAH and NAPE-PLD expression and other components of the endocannabinoid system affects NAE levels in endometrial
cancer. In this figure, we depict the endocannabinoid system in normal endometrium, in type 1 EC and in type 2 EC. In the normal situation (left), endometrial tissue
growth is controlled by a balance between apoptosis and cell proliferation resulting in no net gain of tissue. Relatively high levels of FAAH protein and low levels of
NAPE-PLD protein keep the destruction and production of the NAEs, AEA, OEA, and PEA in the normal range within the tissue. Plasma AEA, OEA, and PEA levels are
also modulated by the actions of NAPE-PLD in endothelial cells and FAAH activities in T-lymphocytes to keep plasma NAE concentrations within the normal range.
The presence of excess estrogen (E2) results in malignant transformation of the endometrium into type 1 EC tissue (middle). Concomitant with that transformation is
an increase in the expression of NAPE-PLD in the tissue and a loss of FAAH, cannabinoid receptor 1 (CBR1) and 2 (CB2R) (23). This allows the NAEs to bind to and
activate GPR55 receptors, which may increase cellular proliferation such that it exceeds the apoptosis effect of AEA binding to the TRPV1 receptor (24). The lack of
CBR1 and CBR2 receptor turnover and the increased synthesis and reduced degradation of NAEs in the tumor, results in excess release of the NAEs into the blood,
where OEA is preferentially degraded by lymphocytic FAAH resulting in the “entourage effect” and the observed higher AEA and PEA concentrations seen in these
patients. Less is known about the role of the endocannabinoid system in type 2 EC (right), but higher NAPE-PLD and lower FAAH, CBR1, and CBR2 expression
values also results in nascent NAE production and release into the blood and similar FAAH degradation of the NAEs as found in type 1 EC. Whether the loss of CBR1
and CBR2 in type 2 EC releases the TRPV1 and GPR55 receptors to respond to the remaining NAE (or other ligands) to affect apoptosis or cell proliferation is
currently unknown, as is the primary initiating factor (black X) or the factor involved in E2 desensitization (white X) that allows drug-resistant forms of type 1 EC to
convert to type 2 EC. In all cases, the synthesis and degradation of the NAEs by endothelial cells and T-lymphocytes, respectively, seems to be unaffected.
providing support for the suggestion that plasma AEA and PEA
concentrations are possibly regulated at the tissue level, if the
relationship between protein expression and enzyme activity
(6, 7, 29, 30) holds true for the endometrium. What is clear is
that both enzymes showed a different pattern of expression that
was related to disease within the tissue.
Whilst FAAH immunoreactivity was distributed throughout
the tissue, NAPE-PLD expression was primarily localized in
the glandular epithelium of EC tissue with increasing intensity
correlating with more advanced and aggressive forms of
the disease.
In summary, the observations presented in this paper indicate
that there is an apparent perturbation in the regulation of the
enzymes that control local tissue and plasma concentrations
of AEA and PEA (and perhaps OEA) in EC. The data also
explain the observed changes in plasma NAEs of patients with
EC and suggests a possible control point in the etiopathogenesis
of EC.
CONCLUSION
Our data show that both enzymes are expressed in EC
and furthermore that they are differentially regulated
with regards to the type of tumor present. The data
also suggest that the main regulator of plasma AEA and
PEA concentrations in post-menopausal women with
endometrial cancer is unlikely to be lymphocytic FAAH
activity, as has been demonstrated in other studies on
endocannabinoid regulation (7–9), but is likely to be due
to endometrial cancer cell FAAH and NAPE-PLD protein
expression levels.
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